新型磷酸二酯酶3/4双重抑制剂治疗慢性阻塞性肺疾病的研究进展  

Research prospect of cyclic nucleotide phosphodiesterase 3/4 inhibitors in chronic obstructive pulmonary disease

作　　者：王梓晖 吴繁 邓志珊 戴翠琼 蔡冠南 周玉民 Wang Zihui;Wu Fan;Deng Zhishan;Dai Cuiqiong;Cai Guannan;Zhou Yumin(National Clinical Research Center for Respiratory Disease,National Center for Respiratory Medicine,Department of Respiratory and Critical Care Medicine,Guangzhou Institute of Respiratory Health,First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Guangzhou National Laboratory,National Clinical Research Center for Respiratory Disease,National Center for Respiratory Medicine,Department of Respiratory and Critical Care Medicine,Guangzhou Institute of Respiratory Health,First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510000,China)

机构地区：[1]呼吸疾病全国重点实验室,国家呼吸系统疾病临床医学研究中心,国家呼吸医学中心,广州呼吸健康研究院,广州医科大学附属第一医院,广州医科大学,广州510120 [2]广州国家实验室,呼吸疾病全国重点实验室,国家呼吸系统疾病临床医学研究中心,国家呼吸医学中心,广州呼吸健康研究院,广州医科大学附属第一医院,广州医科大学,广州510000

出　　处：《中华结核和呼吸杂志》2024年第9期876-884,共9页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：广州国家实验室自立项目(SRPG22-016,SRPG22-018);广东省“珠江人才计划”本土创新科研团队项目(2017BT01S155);“十三五”国家重点研发计划(2016YFC1304101);呼吸疾病全国重点实验室临床及流行病学研究专项(SKLRD-L-202402)。

摘　　要：慢性阻塞性肺疾病(简称慢阻肺)当前治疗方法相对有限,无法满足所有患者的治疗需求。环核苷酸磷酸二酯酶3/4(cyclic nucleotide phosphodiesterases 3/4,PDE3/4)抑制剂的代表药物Ensifentrine(研发代号RPL554)在治疗慢阻肺方面不断取得进展,需及时总结归纳。本文围绕Ensifentrine的化学结构、药物代谢动力学、作用机制、有效性、安全性等方面,归纳总结临床研究进展,并提出临床方面的应用意见和研究展望。Current treatments for chronic obstructive pulmonary disease(COPD)are relatively limited and cannot meet the needs of all patients.Ensifentrine(development code RPL554),a representative drug of cyclic nucleotide phosphodiesterase 3/4(PDE 3/4)inhibitors,has shown promising developments in the treatment of COPD in recent years,which need to be summarized.This article reviews the mechanism and clinical research progress of ensifentrine,focusing on its chemical structure,pharmacokinetics,pathophysiological mechanism,efficacy,and safety.Additionally,we provide clinical application suggestions and future research prospects.

关 键 词：临床研究进展 双重抑制剂 药物代谢动力学 磷酸二酯酶 治疗需求 慢阻肺 慢性阻塞性肺疾病 

分 类 号：R563.9[医药卫生—呼吸系统]